George W. Wright
A5086207316- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Ubiquitin and proteasome pathways
- Immune Cell Function and Interaction
- Glycosylation and Glycoproteins Research
- Viral-associated cancers and disorders
- T-cell and Retrovirus Studies
- Cancer-related gene regulation
- Breast Lesions and Carcinomas
- NF-κB Signaling Pathways
- Protein Degradation and Inhibitors
- Cancer-related molecular mechanisms research
- Acute Lymphoblastic Leukemia research
- CNS Lymphoma Diagnosis and Treatment
- Cutaneous lymphoproliferative disorders research
- Molecular Biology Techniques and Applications
- Cancer and Skin Lesions
- Cancer Genomics and Diagnostics
- Chromatin Remodeling and Cancer
- Genetic factors in colorectal cancer
- Occupational and environmental lung diseases
- RNA modifications and cancer
National Cancer Institute
2015-2024
Center for Cancer Research
2008-2024
National Institutes of Health
2015-2024
University of Arizona
2011-2024
University of Maryland Medical Center
2024
National Center for Advancing Translational Sciences
2024
University of Maryland, Baltimore
2024
Arizona Western College
2024
Cancer Institute (WIA)
2022
Texas A&M University
2020
The survival of patients with diffuse large-B-cell lymphoma after chemotherapy is influenced by molecular features the tumors. We used gene-expression profiles these lymphomas to develop a predictor survival.
Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B-cell–like [ABC], germinal-center [GCB], unclassified) according to cell origin that associated with a differential response chemotherapy targeted agents. We sought extend these findings by identifying genetic subtypes based on shared genomic abnormalities uncover therapeutic vulnerabilities tumor genetics.
The addition of rituximab to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or R-CHOP, has significantly improved the survival patients diffuse large-B-cell lymphoma. Whether gene-expression signatures correlate after treatment lymphoma is unclear.We profiled gene expression in pretreatment biopsy specimens from 181 who received CHOP 233 this disease R-CHOP. A multivariate gene-expression-based survival-predictor model derived a training...
Patients with follicular lymphoma may survive for periods of less than 1 year to more 20 years after diagnosis. We used gene-expression profiles tumor-biopsy specimens obtained at diagnosis develop a molecular predictor the length survival.Gene-expression profiling was performed on 191 biopsy from patients untreated lymphoma. Supervised methods were discover expression patterns associated survival in training set 95 specimens. A constructed these genes and validated an independent test 96...
Using current diagnostic criteria, primary mediastinal B cell lymphoma (PMBL) cannot be distinguished from other types of diffuse large (DLBCL) reliably. We used gene expression profiling to develop a more precise molecular diagnosis PMBL. PMBL patients were considerably younger than DLBCL patients, and their lymphomas frequently involved thoracic structures but not extrathoracic sites typical DLBCLs. had relatively favorable clinical outcome, with 5-yr survival rate 64% compared 46% for...
To classify cancer specimens by their gene expression profiles, we created a statistical method based on Bayes' rule that estimates the probability of membership in one two subgroups. We used this to diffuse large B cell lymphoma (DLBCL) biopsy samples into subgroups data obtained from spotted cDNA microarrays. The germinal center cell-like (GCB) DLBCL subgroup expressed genes characteristic normal cells whereas activated (ABC) subset are plasma cells, particularly those encoding endoplasmic...
Gene-expression profiling has been used to define 3 molecular subtypes of diffuse large B-cell lymphoma (DLBCL), termed germinal center B-cell-like (GCB) DLBCL, activated (ABC) and primary mediastinal (PMBL). To investigate whether these DLBCL arise by distinct pathogenetic mechanisms, we analyzed 203 biopsy samples high-resolution, genome-wide copy number analysis coupled with gene-expression profiling. Of 272 recurrent chromosomal aberrations that were associated alterations, 30...
The distinction between Burkitt's lymphoma and diffuse large-B-cell is crucial because these two types of require different treatments. We examined whether gene-expression profiling could reliably distinguish from lymphoma.Tumor-biopsy specimens 303 patients with aggressive lymphomas were profiled for gene expression also classified according to morphology, immunohistochemistry, detection the t(8;14) c-myc translocation.A classifier based on correctly identified all 25 pathologically...
Purpose Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC translocations, or without BCL2 have been associated inferior survival DLBCL. We investigated whether expression protein, protein expression, could risk-stratify at diagnosis. Patients Methods determined the correlation between presence proteins by immunohistochemistry (IHC) two independent cohorts DLBCL R-CHOP....
Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma. In least curable (ABC) subtype DLBCL, survival malignant cells dependent on constitutive activation nuclear factor-kappaB (NF-kappaB) signaling pathway. normal cells, antigen receptor-induced NF-kappaB requires CARD11, a cytoplasmic scaffolding protein. To determine whether CARD11 contributes to tumorigenesis, we sequenced gene in human DLBCL tumors. We detected missense mutations 7 73 ABC biopsies...
Primary mediastinal B-cell lymphoma is a distinct subtype of diffuse large-B-cell that closely related to nodular sclerosing Hodgkin's lymphoma. Patients are usually young and present with large masses. There no standard treatment, but the inadequacy immunochemotherapy alone has resulted in routine consolidation radiotherapy, which potentially serious late effects. We aimed develop strategy improves rate cure obviates need for radiotherapy.